Biogen Idec (Nasdaq: BIIB) said Wednesday that an advanced study of its drug candidate for hemophilia A, the most common type of hemophilia, showed that the drug is longer-lasting than the currently-approved drug on the market in many patients, and therefore fewer injections are needed.